(Q51490108)

5 April 2018

title

The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. (English)

1 reference

5 April 2018

0 references

4

Julia M L Brotherton

1 reference

5 April 2018

Karen Canfell

6

Karen Canfell

1 reference

5 April 2018

Megan Smith

1

Megan A Smith

1 reference

5 April 2018

Carolyn Nickson

5

Carolyn Nickson

1 reference

5 April 2018

Jie-Bin Lew

2

Jie-Bin Lew

1 reference

5 April 2018

author name string

Robert J Walker

3

1 reference

5 April 2018

language of work or name

English

0 references

publication date

17 March 2011

1 reference

5 April 2018

published in

Vaccine

1 reference

5 April 2018

volume

29

1 reference

5 April 2018

issue

48

1 reference

5 April 2018

page(s)

9112-9122

1 reference

5 April 2018

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Cancers attributable to human papillomavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

The predicted impact of vaccination on human papillomavirus infections in Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Case-control study of human papillomavirus and oropharyngeal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Systematic review of human papillomavirus prevalence in invasive penile cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Histological characteristics of human papilloma-virus-positive and -negative invasive and in situ squamous cell tumours of the penis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Human papillomavirus prevalence and type distribution in penile carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Evaluating human papillomavirus vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Impact of vaccinating boys and men against HPV in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Oropharyngeal cancer epidemic and human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Sex in Australia: sexual identity, sexual attraction and sexual experience among a representative sample of adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Sexual practices, sexually transmitted diseases, and the incidence of anal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Sex in Australia: sexually transmissible infection and blood-borne virus history in a representative sample of adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

What men who have sex with men think about the human papillomavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Determinants of Prevalence, Acquisition, and Persistence of Human Papillomavirus in Healthy Mexican Military Men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

A 2‐Year Prospective Study of Human Papillomavirus Persistence among Women with a Cytological Diagnosis of Atypical Squamous Cells of Undetermined Significance or Low‐Grade Squamous Intraepithelial Lesion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

High-risk HPV type-specific clearance rates in cervical screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.091

10.1016/J.VACCINE.2011.02.091

7 January 2021

Identifiers

DOI

1 reference

5 April 2018

1 reference

5 April 2018